TP53 and B-cell chronic lymphocytic leukemia: O-GlcNAcylation may also have different effects on specific AML subtypes and a detailed characterization of the genetic makeup of the AML cell or perhaps consideration of the state of the p53 axis as in CLL (62) may be required to know if inhibition or enhancement of O-GlcNAcylation is the appropriate treatment strategy.